Edition:
United States

Steadymed Ltd (STDY.OQ)

STDY.OQ on NASDAQ Stock Exchange Global Market

3.45USD
11:51am EST
Change (% chg)

$-0.20 (-5.48%)
Prev Close
$3.65
Open
$3.65
Day's High
$3.65
Day's Low
$3.45
Volume
3,892
Avg. Vol
13,830
52-wk High
$9.65
52-wk Low
$2.55

Select another date:

Fri, Dec 8 2017

BRIEF-SteadyMed Announces FDA Agreed Pathway To Trevyent NDA Resubmission

* STEADYMED ANNOUNCES FDA AGREED PATHWAY TO TREVYENT NDA RESUBMISSION

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

BRIEF-Steadymed reports Q3 earnings per share $0.35

* Steadymed reports third quarter 2017 financial results and provides corporate update

BRIEF-Steadymed receives notice of allowance for European patent

* Steadymed receives notice of allowance for its European patent relating to enhanced reduction of infusion-site pain Source text for Eikon: Further company coverage:

BRIEF-SteadyMed submits type A meeting request package to FDA

* SteadyMed Ltd - ‍type A meeting is being requested in response to FDA's August 28, refusal to file letter relating to co's NDA for Trevyent​ Source text for Eikon: Further company coverage:

BRIEF-SteadyMed receives refusal to file letter from FDA for Trevyent new drug application

* SteadyMed Ltd - FDA determined that application is not sufficiently complete to permit a substantive review

BRIEF-Steadymed Ltd reports Q2 loss per share of $0.33

* Steadymed reports second quarter 2017 financial results and provides corporate update

Select another date: